Abstract 119P
Background
To conduct a comparative analysis of the effectiveness of hypofractional and classical radiotherapy regimens in neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC).
Methods
This study based on a retrospective analysis of a database in patients with LARC who underwent a course of neoadjuvant chemoradiotherapy followed by surgery. The patients were divided into two groups: the first (main) group, 104 patients who underwent a course of hypofractionated chemotherapy (4 Gy x 40 Gy 3 fractions per week) in combination with capecitabine 1650 mg/m2 in two doses. The second group (control group) included 120 patients who underwent a course of CRT in the classical fractionation regimen (2 Gy x 50-58 Gy 5 fractions per week) in combination with capecitabine 1650 mg/m2 in two doses. The main evaluated indicators are the frequency of pCR and cCR. Additional assessed indicators are the severity of early radiation toxicity, the frequency of local relapses, overall and disease-free survival.
Results
The study included 224 patients. The average duration of the CRT course in the study group was 22.56 (95% CI from 21.94 to 23.18) days, in the control group - 38.84 (95% CI from 38.12 to 39.54), p=0.0001. Radiation toxicity grade III and IV was registered in 5.75% of patients in the study group and in 6.41% of patients in the control group. pCR in the study groups was achieved in 19.23% and 15.83% of cases, respectively, p=0.504. The cCR in the studied groups was achieved in 25% and 18.3% of cases, respectively, p=0.226. The median time without progression was 37.6 months. In the main and control groups, local control rates were 91.34% and 88.3% respectively, p=0.954, HR=1.05 (95% CI 0.21 to 5.22). Five-year disease-free survival in the main group was 71.1% and in the control group 60.8%, respectively, p=0.353, HR=0.79 (95% CI 0.42 to 1.35). Five-year overall survival in the main and control groups were 81.7% and 79.2%, respectively, p=0.743, HR=0.87 (95% CI 0.39 to 1.92).
Conclusions
Thus, the hypofractionation regimen showed high antitumor efficacy and can be considered as an alternative and not inferior to the classical regimen in neoadjuvant CRT in patients with LARC.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract